Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 6;333(17):1540-1543.
doi: 10.1001/jama.2025.1225.

Genomic Characterization of RSV in the US by Vaccination Status

Adam S Lauring  1 , Connor Edson  2 , Diya Surie  3 , Fatimah S Dawood  3 , Wesley H Self  4 , Cynthia Lucero-Obusan  5   6 , Mark Holodniy  2 ; IVY Network
Collaborators, Affiliations

Genomic Characterization of RSV in the US by Vaccination Status

Adam S Lauring et al. JAMA. .
No abstract available

Plain language summary

This study examines respiratory syncytial virus (RSV) genomic surveillance results from 2 large US networks after the introduction of RSV vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lauring reported receiving personal fees from Roche outside the submitted work. Dr Self reported receiving grants from the Centers for Disease Control and Prevention during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Time-Resolved Phylogenetic Tree of Respiratory Syncytial Virus (RSV)-B F Gene
Time-resolved maximum likelihood phylogenetic tree of 270 RSV-B sequences from US adults September 2023 to April 2024 and 70 contextual RSV-B sequences from 2022-2023 in the Investigating Respiratory Viruses in the Acutely Ill network, available on GISAID.org. The heat map shows amino acid substitutions (top) in antigenic sites identified across the cohort relative to the reference sequence hRSV/B/Australia/VIC-RCH056/2019 (EPI_ISL_1653999).
See this image and copyright information in PMC

References

    1. Shi T, McAllister DA, O’Brien KL, et al. ; RSV Global Epidemiology Network . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958. doi: 10.1016/S0140-6736(17)30938-8 - DOI - PMC - PubMed
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-1759. doi: 10.1056/NEJMoa043951 - DOI - PubMed
    1. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233-245. doi: 10.1038/s41579-019-0149-x - DOI - PMC - PubMed
    1. Gilman MSA, Castellanos CA, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016;1(6):eaaj1879. doi: 10.1126/sciimmunol.aaj1879 - DOI - PMC - PubMed
    1. Papi A, Ison MG, Langley JM, et al. ; AReSVi-006 Study Group . Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595-608. doi: 10.1056/NEJMoa2209604 - DOI - PubMed